Equities analysts expect Wave Life Sciences Ltd (NASDAQ:WVE) to report earnings of ($1.48) per share for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Wave Life Sciences earnings, with estimates ranging from ($1.81) to ($1.21). Wave Life Sciences posted earnings of ($1.29) per share during the same quarter last year, which would indicate a negative year over year growth rate of 14.7%. The business is scheduled to report its next earnings report on Friday, March 6th.
According to Zacks, analysts expect that Wave Life Sciences will report full year earnings of ($5.54) per share for the current year, with EPS estimates ranging from ($5.87) to ($5.27). For the next year, analysts anticipate that the firm will post earnings of ($3.18) per share, with EPS estimates ranging from ($4.77) to ($1.61). Zacks EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Wave Life Sciences.
A number of equities research analysts recently weighed in on the stock. SunTrust Banks restated a buy rating and set a $20.00 price objective on shares of Wave Life Sciences in a research note on Tuesday, December 31st. Guggenheim cut their price objective on shares of Wave Life Sciences from $43.00 to $25.00 and set a buy rating on the stock in a research note on Tuesday, December 17th. Zacks Investment Research upgraded shares of Wave Life Sciences from a hold rating to a buy rating and set a $9.25 price objective on the stock in a research note on Saturday, January 11th. Leerink Swann cut shares of Wave Life Sciences from an outperform rating to a market perform rating and cut their price objective for the company from $33.00 to $10.00 in a research note on Tuesday, December 31st. Finally, Mizuho assumed coverage on shares of Wave Life Sciences in a research note on Monday, December 30th. They set a buy rating and a $65.00 price objective on the stock. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Wave Life Sciences has an average rating of Buy and a consensus target price of $22.75.
A number of institutional investors have recently modified their holdings of the business. Assenagon Asset Management S.A. acquired a new stake in Wave Life Sciences during the 4th quarter worth about $538,000. Redmile Group LLC grew its stake in Wave Life Sciences by 16.8% during the 3rd quarter. Redmile Group LLC now owns 3,177,760 shares of the companys stock valued at $65,239,000 after acquiring an additional 458,053 shares in the last quarter. Barclays PLC grew its stake in Wave Life Sciences by 39.5% during the 3rd quarter. Barclays PLC now owns 23,459 shares of the companys stock valued at $482,000 after acquiring an additional 6,647 shares in the last quarter. Point72 Asset Management L.P. grew its stake in Wave Life Sciences by 3.4% during the 3rd quarter. Point72 Asset Management L.P. now owns 45,000 shares of the companys stock valued at $924,000 after acquiring an additional 1,500 shares in the last quarter. Finally, Matisse Capital grew its stake in Wave Life Sciences by 9.3% during the 3rd quarter. Matisse Capital now owns 66,486 shares of the companys stock valued at $1,365,000 after acquiring an additional 5,660 shares in the last quarter. Hedge funds and other institutional investors own 90.26% of the companys stock.
Shares of NASDAQ WVE opened at $7.71 on Thursday. Wave Life Sciences has a fifty-two week low of $6.89 and a fifty-two week high of $48.64. The firms 50-day simple moving average is $9.37 and its 200 day simple moving average is $20.50. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.88 and a current ratio of 1.88.
About Wave Life Sciences
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Recommended Story: Technical Indicators What is a Golden Cross?
Get a free copy of the Zacks research report on Wave Life Sciences (WVE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
Read the rest here:
Analysts Anticipate Wave Life Sciences Ltd (NASDAQ:WVE) Will Announce Earnings of -$1.48 Per Share - Slater Sentinel
Recommendation and review posted by G. Smith
